Palisade bio announces european patent office issued a decision to grant notice for patent for lead product candidate, pali-2108

Patent includes composition of matter claims for both pali-2108 and pali-1908 programs patent includes broad claims for “gut microbiota bioactivated pde4 inhibitor precursors” with similar structure to pali-2108 and pali-1908 this patent family provides composition of matter coverage beyond 2042 pali-2108 is in development to treat patients with active moderate-to-severely active ulcerative colitis (uc) pali-1908 is in development to treat patients with active fibro stenotic crohn's disease (cd) carlsbad, ca, july 19, 2024 (globe newswire) -- palisade bio, inc.  (nasdaq: pali) (the “company”), a biopharmaceutical company focused on developing and advancing novel therapeutics for patients living with autoimmune, inflammatory, and fibrotic diseases, today announced that european patent office (epo) has issued a decision to grant notice for patent number 4,157,853 titled, “gut microbiota bioactivated pde4 inhibitor precursors.” based on the intention to grant notice, the company expects the epo to issue a patent july 31, 2024.
PALI Ratings Summary
PALI Quant Ranking